Physical Exercise-Induced FGF-21 to Fight Obesity: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Bruno Vecchiatto
,
Thiago Lucas de Castro
,
Cynthia R. Muller
,
Anna Karenina Azevedo-Martins
,
Fabiana S. Evangelista

Fibroblast growth factor 21 (FGF-21) is a protein that is involved in the regulation of glucose, lipids, and energy metabolism. To act on target tissues, endocrine FGF-21 binds preferably to FGF receptor 1 (FGFR1) in the presence of the coreceptor named β-klotho (KLB). Some of the effects of FGF-21 include increased fatty acid oxidation, glucose uptake, insulin sensitivity, and thermogenesis, which can regulate body weight and glycemia control. By exerting such metabolic effects, the therapeutic potential of FGF-21 for the treatment of obesity and diabetes has been investigated. Physical exercise has been widely used for the prevention and treatment of obesity. Several mechanisms mediate the effects of physical exercise, including the FGF-21 pathway. Studies have shown that physical exercise increases the concentration of circulating and tissue FGF-21 in animals, while contradictory results are still observed in humans.

  • FGF-21
  • physical exercise
  • obesity

1. Introduction

Fibroblast growth factor 21 (FGF-21), a protein with a molecular weight of 23 kDa, is produced in the liver, heart, pancreas, white adipose tissue (WAT), brown adipose tissue (BAT), skeletal muscle, and brain [1], and its action is mediated by the interaction of the transmembrane protein β-Klotho (KLB) with the receptors FGFR1, FGFR2, FGFR3, and FGFR4 [2].
Among other endocrine functions, FGF-21 is known as a potent metabolic modulator, since it stimulates glucose uptake and increases fatty acid oxidation by activating coactivator 1 alpha of the peroxisome proliferator-activated receptor gamma (PGC-1⍺) [3]. Administration of FGF-21 to rats fed a high-fat diet reduces body weight and visceral fat gain, and increases insulin sensitivity [4]. Apparently, its effect is associated with increased energy expenditure [5], increased fatty acid oxidation, and reduced adiposity and body mass [6]. By exerting such metabolic effects, the therapeutic potential of FGF-21 for the treatment of obesity and diabetes has been the subject of human studies [7].
Obesity has become a significant public health issue worldwide, and strategies to combat the high prevalence are necessary because it causes damage to health and is a financial burden on people and society. Physical exercise has been widely used for the prevention and treatment of obesity. This is because it has the potential to increase lipid oxidation, reduce fat mass, increase insulin sensitivity, and lower blood glucose, as described by some research groups [8][9] and by the researchers' groups [10][11]. The researchers also showed that physical exercise exerts a protective effect diminishing lipid deposition in the kidneys of mice with insulin resistance [12] and by modifying the skeletal muscle proteins expression to a more oxidative phenotype [13] in an animal model of obesity.

2. FGF-21 Metabolic Effects

FGF is a large protein family, with 22 members in mammals. Based on gene sequence homology and phylogeny, the FGF family can be divided into seven subfamilies, among which the endocrine FGF-19 subfamily consists of three FGFs, namely FGF-19 (FGF-15 in rodents), FGF-21, and FGF-23 [14]. In order to act on target tissues, FGF-21 binds to FGF receptor 1 (FGFR1) in the presence of the transmembrane protein named β-klotho [15][16]. FGF-21 can also act by other receptors, such as FGFR2, FGFR3, and FGFR4, however it prefers to bind to FGFR1 over these other receptors [17].
Kharitonenkov et al. (2005) were the first to describe FGF-21 as a possible metabolic regulator [5]. They observed that transgenic mice expressing human FGF-21 submitted to high-fat diet for 15 weeks were resistant to obesity, and presented lower levels of fasting glucose and leptin. They also showed that FGF-21 indirectly exerts hypoglycemic effects by inhibiting glucagon secretion. Other studies have reported beneficial effects of FGF-21, including reduction in body weight, liver and circulating triglycerides, fasting plasma insulin and glucose, and increase in energy expenditure [3][18]. Interestingly, obesity and type 2 diabetes have also been associated with increased circulating FGF-21 concentration in humans [19] and animals [20]. The paradoxical effect of FGF-21 was first explained by the FGF-21 resistance associated with lower expression of KLB and FGFR1 [21], but this was contradicted in a recent review by [22].
FGF-21 exerts metabolic effects on several tissues (Figure 1). In the liver, FGF21 stimulates fatty acid oxidation and reduces lipid flux by increasing peripheral lipoprotein catabolism and reducing adipocyte lipolysis [23]. In the white adipose tissue (WAT), it suppresses lipolysis and enhances insulin sensitivity and adiponectin secretion [23][24], thus ameliorating some harmful effects of obesity, such as hyperglycemia, glucose intolerance, insulin resistance, and dyslipidemia [25][26]. In the brown adipose tissue (BAT), FGF-21 increases glucose uptake, lipolysis, and thermogenesis [27]. Other tissue actions of the FGF-21 can be found in the review published by She et al. (2022) [14].
Figure 1. Metabolic effects of FGF-21 that may contribute to the body weight and glycemia control. Arrows indicate the following: upward, increase; downward, decrease. WAT = white adipose tissue; BAT = brown adipose tissue.

3. Effect of Physical Exercise on FGF-21

Physical exercise acts in different ways in the body, as it can alter protein secretion, influencing circulating but also locally levels. A continuous aerobic exercise session increases the circulating FGF-21 in both lean and obese individuals immediately after exercise for up to one hour [28]. Interestingly, a high-intensity interval training (HIIT) session appears to prolong the increased levels of FGF-21 induced by the exercise up to 3 h after the end of the session in lean men, while this effect can last for up to 48 h when the resistance exercise with seven types of exercises targeting all the main muscle groups was performed [29]. In obese people submitted to acute moderate-intensity exercise (treadmill exercise, ∼60% peak oxygen uptake), circulating concentrations of FGF21 were elevated after exercise for up to 6 h [30]. Based on research, it seems that resistance exercise session is the type of exercise that keeps the FGF-21 level higher for longer post-acute exercise.
It is important to point out that the acute exercise effect on FGF-21 is not a consensus in the literature. Cuevas-Ramos et al. (2012) [31] and Parmar et al. (2018) [32] observed no significant changes in serum FGF21 of lean individuals after a single session of aerobic exercise and resistance exercise, respectively. A summary of the effects of physical exercise on circulating FGF-21 in lean and obese individuals is demonstrated in the Figure 2. It appears that the intensity of the aerobic exercise affects the FGF-21 secretion response. In fact, He et al. (2019) [33] that showed a higher serum concentration of FGF-21 after performing exercise at 90% of maximum heart rate (HR max) in comparison to an exercise performed at 69% of HR max. Furthermore, the correlation between exercise volume and the levels of FGF-21 remains unclear and it is suggested that endogenous FGF-21 is associated with the magnitude of caloric expenditure and oxidative stress caused by acute strenuous physical exercise [34]. This gap remains, and further studies are needed to confirm this hypothesis.
Figure 2. Effects of acute and chronic exercise in different modalities for circulating FGF-21 in lean and obese individuals. Arrows indicate the following: upward, increase in FGF-21; bidirectional, no change in FGF-21; downward, decrease in FGF-21. Dot = unknown.
The chronic physical exercise effect on FGF-21 has been extensively investigated. In lean individuals, a significant increase in FGF21 concentration was shown after two weeks of treadmill training [31]. On the other hand, Mendez-Gutierrez et al. (2022) [35] did not find difference in FGF-21 plasma concentration after a 24-week exercise program (continuous aerobic exercise + resistance). As discussed previously, differences in exercise protocols, age, and sex of participants can explain the results [36].
As physical exercise is the focus of this topic, it is important to highlight its potential to alter the characteristics of adipose tissue, increasing adipokine secretion, heat production, and caloric expenditure. It is known that obese and elderly individuals have less activation of BAT [37], which makes BAT a target of studies in possible treatments. Studies have also already shown that physical exercise in humans has the potential to modify characteristics of BAT, increasing the expression of UCP1 and fatty acid transporters in people with obesity, but not overweight [38][39]. Other studies have already shown that the crosstalk of WAT to BAT is associated with greater tissue expression of FGF-21 [40]. However, more studies are needed to investigate the effect of physical exercise on the synthesis of FGF-21 in adipose tissue, and its potential to alter its characteristics enabling greater heat production and energy expenditure.

This entry is adapted from the peer-reviewed paper 10.3390/obesities2040031

References

  1. Staiger, H.; Keuper, M.; Berti, L.; de Angelis, M.H.; Häring, H.U. Fibroblast growth factor 21-metabolic role in mice and men. Endocr. Rev. 2017, 38, 468–488.
  2. Itoh, N.; Ohta, H.; Konishi, M. Endocrine FGFs: Evolution, Physiology, Pathophysiology, and Pharmacotherapy. Front. Endocrinol. 2015, 6, 154.
  3. Huang, Z.; Xu, A.; Cheung, B.M.Y. The Potential Role of Fibroblast Growth Factor 21 in Lipid Metabolism and Hypertension. Curr. Hypertens. Rep. 2017, 19, 17–22.
  4. Charoenphandhu, N.; Suntornsaratoon, P.; Krishnamra, N. Fibroblast growth factor—21 restores insulin sensitivity but induces aberrant bone microstructure in obese insulin—Resistant rats. J. Bone Miner. Metab. 2016, 35, 142–149.
  5. Kharitonenkov, A.; Shiyanova, T.L.; Koester, A.; Ford, A.M.; Micanovic, R.; Galbreath, E.J.; Sandusky, G.E.; Hammond, L.J.; Moyers, J.S.; Owens, R.A.; et al. FGF-21 as a novel metabolic regulator. J. Clin. Investig. 2005, 115, 1627–1635.
  6. Coskun, T.; Bina, H.A.; Schneider, M.A.; Dunbar, J.D.; Hu, C.C.; Chen, Y.; Moller, D.E.; Kharitonenkov, A. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008, 149, 6018–6027.
  7. Jimenez, V.; Jambrina, C.; Casana, E.; Sacristan, V.; Muñoz, S.; Darriba, S.; Rodó, J.; Mallol, C.; Garcia, M.; León, X.; et al. FGF21 gene therapy as treatment for obesity and insulin resistance. EMBO Mol. Med. 2018, 10, e8791.
  8. Venables, M.C.; Jeukendrup, A.E. Endurance training and obesity: Effect on substrate metabolism and insulin sensitivity. Med. Sci. Sports Exerc. 2008, 40, 495–502.
  9. Winding, K.M.; Munch, G.W.; Iepsen, U.W. The effect of low-volume high-intensity interval training versus endurance training on glycemic control in individuals with type 2 diabetes. Diabetes Obes. Metab. 2018, 20, 1131–1139.
  10. Higa, T.S.; Spinola, A.V.; Fonseca-Alaniz, M.H.; Evangelista, F.S. Remodeling of white adipose tissue metabolism by physical training prevents insulin resistance. Life Sci. 2014, 103, 41–48.
  11. Américo, A.L.V.; Muller, C.R.; Vecchiatto, B.; Martucci, L.F.; Fonseca-Alaniz, M.H.; Evangelista, F.S. Aerobic exercise training prevents obesity and insulin resistance independent of the renin angiotensin system modulation in the subcutaneous white adipose tissue. PLoS ONE 2019, 14, e0215896.
  12. Muller, C.R.; Américo, A.L.V.; Fiorino, P.; Evangelista, F.S. Aerobic exercise training prevents kidney lipid deposition in mice fed a cafeteria diet. Life Sci. 2018, 211, 140–146.
  13. Vecchiatto, B.; da Silva, R.C.; Higa, T.S.; Muller, C.R.; Américo, A.L.V.; Fortunato-Lima, V.C.; Ferreira, M.M.; Martucci, L.F.; Fonseca-Alaniz, M.H.; Evangelista, F.S. Oxidative phenotype induced by aerobic physical training prevents the obesity-linked insulin resistance without changes in gastrocnemius muscle ACE2-Angiotensin(1-7)-Mas axis. Diabetol. Metab. Syndr. 2021, 13, 74.
  14. She, Q.-Y.; Bao, J.; Wang, H.; Liang, H. Fibroblast growth factor 21: A “rheostat” for metabolic regulation? Metabolism. 2022, 130, 155166.
  15. Badman, M.K.; Pissios, P.; Kennedy, A.R.; Koukos, G.; Flier, J.S.; Maratos-Flier, E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007, 5, 426–437.
  16. Inagaki, T.; Dutchak, P.; Zhao, G.; Ding, X.; Gautron, L.; Parameswara, V.; Li, Y.; Goetz, R.; Mohammadi, M.; Esser, V.; et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 2007, 5, 415–425.
  17. Ding, X.; Boney-Montoya, J.; Owen, B.M.; Bookout, A.L.; Coate, K.C.; Mangelsdorf, D.J.; Kliewer, S.A. βKslotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab. 2012, 16, 387–393.
  18. Geng, L.; Lam, K.S.L.; Xu, A. The therapeutic potential of FGF21 in metabolic diseases: From bench to clinic. Nat. Rev. Endocrinol. 2020, 16, 654–667.
  19. Zhang, X.; Yeung, D.C.Y.; Karpisek, M.; Stejskal, D.; Zhou, Z.-G.; Liu, F.; Wong, R.L.C.; Chow, W.-S.; Tso, A.W.K.; Lam, K.S.L.; et al. Serum FGF21 Levels Are Increased in Obesity and Are Independently Associated With the Metabolic Syndrome in Humans. Diabetes 2008, 57, 1246–1253.
  20. Hale, C.; Chen, M.M.; Stanislaus, S.; Chinookoswong, N.; Hager, T.; Wang, M.; Véniant, M.M.; Xu, J. Lack of Overt FGF21 Resistance in Two Mouse Models of Obesity and Insulin Resistance. Endocrinology 2012, 153, 69–80.
  21. Fisher, f.M.; Chui, P.C.; Antonellis, P.J.; Bina, H.A.; Kharitonenkov, A.; Flier, J.S.; Maratos-Flier, E. Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State. Diabetes 2010, 59, 2781–2789.
  22. Spann, R.A.; Morrison, C.D.; den Hartigh, L.J. The Nuanced Metabolic Functions of Endogenous FGF21 Depend on the Nature of the Stimulus, Tissue Source, and Experimental Model. Front. Endocrinol. 2022, 12, 1–21.
  23. Kaufman, A.; Abuqayyas, L.; Denney, W.S.; Tillman, E.J.; Rolph, T. AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients. Cell Reports Med. 2020, 1, 100057.
  24. Turer, A.T.; Scherer, P.E. Adiponectin: Mechanistic insights and clinical implications. Diabetologia 2012, 55, 2319–2326.
  25. Yamauchi, T.; Kamon, J.; Minokoshi, Y.; Ito, Y.; Waki, H.; Uchida, S.; Yamashita, S.; Noda, M.; Kita, S.; Ueki, K.; et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 2002, 8, 1288–1295.
  26. Xu, A.; Wang, Y.; Keshaw, H.; Xu, L.Y.; Lam, K.S.L.; Cooper, G.J.S. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J. Clin. Investig. 2003, 112, 91–100.
  27. Babaknejad, N.; Nayeri, H.; Hemmati, R.; Bahrami, S.; Esmaillzadeh, A. An Overview of FGF19 and FGF21: The Therapeutic Role in the Treatment of the Metabolic Disorders and Obesity. Horm. Metab. Res. 2018, 50, 441–452.
  28. Khalafi, M.; Alamdari, K.A.; Symonds, M.E.; Nobari, H.; Carlos-Vivas, J. Impact of acute exercise on immediate and following early post-exercise FGF-21 concentration in adults: Systematic review and meta-analysis. Hormones 2021, 20, 23–33.
  29. He, Z.; Tian, Y.; Valenzuela, P.L.; Huang, C.; Zhao, J.; Hong, P.; He, Z.; Yin, S.; Lucia, A. Myokine Response to High-Intensity Interval vs. Resistance Exercise: An Individual Approach. Front. Physiol. 2018, 9, 1735.
  30. Sargeant, J.A.; Aithal, G.P.; Takamura, T.; Misu, H.; Takayama, H.; Douglas, J.A.; Turner, M.C.; Stensel, D.J.; Nimmo, M.A.; Webb, D.R.; et al. The influence of adiposity and acute exercise on circulating hepatokines in normal-weight and overweight/obese men. Appl. Physiol. Nutr. Metab. 2018, 43, 482–490.
  31. Cuevas-Ramos, D.; Almeda-Valdés, P.; Meza-Arana, C.E.; Brito-Córdova, G.; Gómez-Pérez, F.J.; Mehta, R.; Oseguera-Moguel, J.; Aguilar-Salinas, C.A. Exercise increases serum fibroblast growth factor 21 (FGF21) levels. PLoS ONE 2012, 7, e38022.
  32. Parmar, B.; Lewis, J.E.; Samms, R.J.; Ebling, F.J.P.; Cheng, C.C.; Adams, A.C.; Mallinson, J.; Cooper, S.; Taylor, T.; Ghasemi, R.; et al. Eccentric exercise increases circulating fibroblast activation protein α but not bioactive fibroblast growth factor 21 in healthy humans. Exp. Physiol. 2018, 103, 876–883.
  33. He, Z.; Tian, Y.; Valenzuela, P.L.; Huang, C.; Zhao, J.; Hong, P.; He, Z.; Yin, S.; Lucia, A. Myokine/adipokine response to “aerobic” exercise: Is it just a matter of exercise load? Front. Physiol. 2019, 10, 691.
  34. Ost, M.; Coleman, V.; Kasch, J.; Klaus, S. Regulation of myokine expression: Role of exercise and cellular stress. Free Radic. Biol. Med. 2016, 98, 78–89.
  35. Mendez-Gutierrez, A.; Aguilera, C.M.; Osuna-Prieto, F.J.; Martinez-Tellez, B.; Rico Prados, M.C.; Acosta, F.M.; Llamas-Elvira, J.M.; Ruiz, J.R.; Sanchez-Delgado, G. Exercise-induced changes on exerkines that might influence brown adipose tissue metabolism in young sedentary adults. Eur. J. Sport Sci. Online ahead of print. 2022.
  36. Domin, R.; Dadej, D.; Pytka, M.; Zybek-Kocik, A.; Ruchała, M.; Guzik, P. Effect of Various Exercise Regimens on Selected Exercise-Induced Cytokines in Healthy People. Int. J. Environ. Res. Public Health 2021, 18, 1261.
  37. Worku, M.G.; Seretew, W.S.; Angaw, D.A.; Tesema, G.A. Prevalence and Associated Factor of Brown Adipose Tissue: Systematic Review and Meta-Analysis. Biomed Res. Int. 2020, 2020, 9106976.
  38. Otero-Díaz, B.; Rodríguez-Flores, M.; Sánchez-Muñoz, V.; Monraz-Preciado, F.; Ordoñez-Ortega, S.; Becerril-Elias, V.; Baay-Guzmán, G.; Obando-Monge, R.; García-García, E.; Palacios-González, B.; et al. Exercise Induces White Adipose Tissue Browning Across the Weight Spectrum in Humans. Front. Physiol. 2018, 9, 1781.
  39. Norheim, F.; Langleite, T.M.; Hjorth, M.; Holen, T.; Kielland, A.; Stadheim, H.K.; Gulseth, H.L.; Birkeland, K.I.; Jensen, J.; Drevon, C.A. The effects of acute and chronic exercise on PGC-1α, irisin and browning of subcutaneous adipose tissue in humans. FEBS J. 2014, 281, 739–749.
  40. Koh, Y.J.; Lee, J.H.; Park, S.Y. Moxibustion-simulating bipolar radiofrequency suppresses weight gain and induces adipose tissue browning via activation of UCP1 and FGF21 in a mouse model of diet-induced obesity. Evid.-Based Complement. Altern. Med. 2018, 2018, 4737515.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
Video Production Service
Feedback